employer cover photo
employer logo
employer logo

Oncolytics Biotech

Is this your company?

Oncolytics Biotech Snapshot

3.3
based on 2 ratings

56% would recommend to a friend

Brad Thompson

56% approve of CEO

Description Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

Life at Oncolytics Biotech

Glassdoor gives you an inside look at what it's like to work at Oncolytics Biotech, including salaries, reviews, office photos and more. This is the Oncolytics Biotech company profile. All content is posted anonymously by employees working at Oncolytics Biotech.